Insys Therapeutics, Inc. (NASDAQ:INSY) saw unusually-strong trading volume on Monday . Approximately 1,609,901 shares were traded during mid-day trading, an increase of 201% from the previous session’s volume of 535,509 shares.The stock last traded at $9.95 and had previously closed at $8.88.

A number of brokerages recently issued reports on INSY. Zacks Investment Research upgraded Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 price objective on the stock in a research note on Wednesday, July 12th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Insys Therapeutics in a report on Tuesday, July 4th. Jefferies Group LLC reiterated a “buy” rating and set a $14.00 target price on shares of Insys Therapeutics in a research report on Friday, June 9th. BidaskClub upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 8th. Finally, Piper Jaffray Companies set a $10.00 target price on shares of Insys Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $13.25.

The company’s market capitalization is $693.52 million. The company has a 50-day moving average price of $9.24 and a 200-day moving average price of $11.02.

Insys Therapeutics (NASDAQ:INSY) last announced its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. The company had revenue of $42.60 million during the quarter, compared to analyst estimates of $36.90 million. During the same period in the previous year, the business posted $0.13 earnings per share. The firm’s quarterly revenue was down 38.4% compared to the same quarter last year. On average, equities research analysts anticipate that Insys Therapeutics, Inc. will post ($0.29) EPS for the current fiscal year.

In related news, CEO Saeed Motahari acquired 5,500 shares of Insys Therapeutics stock in a transaction dated Thursday, August 10th. The shares were purchased at an average price of $8.92 per share, for a total transaction of $49,060.00. Following the completion of the transaction, the chief executive officer now directly owns 15,400 shares in the company, valued at approximately $137,368. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder John N. Kapoor Trust Dated Sept bought 17,500 shares of the stock in a transaction dated Friday, August 11th. The stock was bought at an average cost of $8.93 per share, for a total transaction of $156,275.00. Following the acquisition, the insider now directly owns 31,982 shares of the company’s stock, valued at approximately $285,599.26. The disclosure for this purchase can be found here. 67.90% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the stock. Thrivent Financial For Lutherans bought a new stake in Insys Therapeutics in the 1st quarter valued at $1,058,000. Point72 Asset Management L.P. lifted its stake in Insys Therapeutics by 24.8% in the 1st quarter. Point72 Asset Management L.P. now owns 435,000 shares of the specialty pharmaceutical company’s stock worth $4,572,000 after purchasing an additional 86,373 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Insys Therapeutics by 128.6% during the 2nd quarter. Alliancebernstein L.P. now owns 140,840 shares of the specialty pharmaceutical company’s stock valued at $1,782,000 after purchasing an additional 79,220 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Insys Therapeutics by 105.3% during the 1st quarter. First Trust Advisors LP now owns 147,788 shares of the specialty pharmaceutical company’s stock valued at $1,553,000 after purchasing an additional 75,817 shares during the last quarter. Finally, Quantitative Investment Management LLC bought a new position in shares of Insys Therapeutics during the 2nd quarter valued at about $879,000. Hedge funds and other institutional investors own 25.45% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/04/insys-therapeutics-inc-insy-sees-strong-trading-volume.html.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Stock Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related stocks with our FREE daily email newsletter.